U.S. Markets closed

Novo Nordisk A/S (NOVO-B.CO)

Copenhagen - Copenhagen Real Time Price. Currency in DKK
Add to watchlist
415.10+2.25 (+0.54%)
At close: 4:59PM CET
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close412.85
Open414.60
Bid416.15 x 0
Ask416.20 x 0
Day's Range412.90 - 417.60
52 Week Range331.70 - 467.90
Volume2,295,370
Avg. Volume2,361,964
Market Cap960.699B
Beta (5Y Monthly)0.32
PE Ratio (TTM)23.46
EPS (TTM)17.69
Earnings DateN/A
Forward Dividend & Yield8.60 (2.08%)
Ex-Dividend DateAug 14, 2020
1y Target Est326.96
  • FDA approves Saxenda® for the treatment of obesity in adolescents aged 12-17
    PR Newswire

    FDA approves Saxenda® for the treatment of obesity in adolescents aged 12-17

    Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) approved an updated label for Saxenda® (liraglutide) injection 3 mg for use in the treatment of obesity in adolescents (12–17 years) with a body weight above 60 kg and an initial body mass index (BMI) corresponding to 30 kg/m2 or greater for adults, as an adjunct to reduced-calorie meals and increased physical activity. Saxenda® was approved in 2014 for chronic weight management in adults with a BMI ≥30 kg/m2, or ≥27 kg/m2 with at least one weight-related comorbidity, as an adjunct to a reduced calorie meal plan and increased physical activity.1

  • Novo Nordisk files for US FDA regulatory approval of once-weekly semaglutide 2.4 mg for weight management
    GlobeNewswire

    Novo Nordisk files for US FDA regulatory approval of once-weekly semaglutide 2.4 mg for weight management

    Bagsværd, Denmark, 4 December 2020 – Novo Nordisk today announced the submission of a new drug application (NDA) to the US Food and Drug Administration (FDA) for subcutaneous semaglutide 2.4 mg, a once-weekly glucagon-like peptide-1 (GLP-1) analogue for chronic weight management. A priority review voucher has been applied to the NDA, leading to an anticipated review time of six months from the submission date, according to standard FDA review timelines. The potential indication is for the treatment of adults with obesity (BMI ≥ 30 kg/m2) or overweight (BMI ≥ 27 kg/m2) with at least one weight-related comorbidity, as an adjunct to reduced-calorie diet and increased physical activity.The submission is based on the results from the STEP phase 3a clinical trial programme, which included more than 4,500 adults with obesity or overweight. Across the STEP programme, people with obesity treated with once-weekly semaglutide 2.4 mg achieved a statistically significant and superior reduction in body weight compared to placebo. Across STEP 1, 3 and 4 a weight loss of 15-18% was reported for people treated with semaglutide 2.4 mg. Furthermore, once-weekly semaglutide 2.4 mg appeared to have a safe and well-tolerated profile. The most common side effects were gastrointestinal and were transient, and mild or moderate in severity.  “Obesity is associated with a wide range of serious complications, yet many healthcare providers still do not have sufficient medical options available to help people with this chronic disease ,” said Mads Krogsgaard Thomsen, executive vice president and chief scientific officer of Novo Nordisk. "We are excited about the regulatory filing of semaglutide 2.4 mg in the US and we believe once-weekly semaglutide 2.4 mg has the potential to transform the medical management of obesity."About obesity and subcutaneous semaglutide 2.4 mg for weight management Obesity is a chronic disease that requires long-term management. It is associated with many serious health consequences and decreased life expectancy. Obesity-related complications are numerous and include type 2 diabetes, heart disease, obstructive sleep apnoea, non-alcoholic fatty liver disease and cancer.Once-weekly subcutaneous semaglutide 2.4 mg is being investigated by Novo Nordisk as a potential treatment for obesity. Semaglutide is an analogue of the human glucagon‑like peptide-1 (GLP-1) hormone. It induces weight loss by reducing hunger, increasing feelings of fullness and thereby helping people eat less and reduce their calorie intake.About the STEP clinical programme STEP (Semaglutide Treatment Effect in People with obesity) is a phase 3 clinical development programme with once-weekly subcutaneous semaglutide 2.4 mg in obesity. The global phase 3a programme consists of four trials and has enrolled approximately 4,500 adults with overweight or obesity.STEP 1 – a 68-week safety and efficacy trial of subcutaneous semaglutide 2.4 mg versus placebo in 1,961 adults with obesity or overweight. For more information, please read the company announcement hereSTEP 2 – a 68-week safety and efficacy trial of subcutaneous  semaglutide 2.4 mg versus placebo and once-weekly subcutaneous semaglutide 1.0 mg in 1,210 adults with type 2 diabetes and either obesity or overweight. For more information, please read the company announcement hereSTEP 3 – a 68-week safety and efficacy trial of subcutaneous  semaglutide 2.4 mg versus placebo in combination with intensive behavioural treatment in 611 adults with obesity or overweight. For more information, please read the company announcement hereSTEP 4 – a 68-week safety and efficacy trial of subcutaneous  semaglutide 2.4 mg versus placebo in 803 adults with obesity or overweight who have reached the target dose of 2.4 mg after a 20-week run-in. For more information, please read the company announcement hereAbout Novo Nordisk Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 44,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.Further informationMedia:   Mette Kruse Danielsen+45 3079 3883mkd@novonordisk.com Ken Inchausti (US)+1 609 240 9429kiau@novonordisk.com     Investors:   Daniel Muusmann Bohsen+45 3075 2175dabo@novonordisk.com Valdemar Borum Svarrer+45 3079 0301jvls@novonordisk.com Ann Søndermølle Rendbæk+45 3075 2253arnd@novonordisk.com Mark Joseph Root+45 3079 4211mjhr@novonordisk.com Kristoffer Due Berg (US)+1 609 235 2989krdb@novonordisk.com Company announcement No 74 / 2020Attachment * PR201204_semglutide_obesity_US_submission

  • Novo Nordisk A/S – Share repurchase programme
    GlobeNewswire

    Novo Nordisk A/S – Share repurchase programme

    Novo Nordisk A/S – Share repurchase programmeBagsværd, Denmark, 30 November 2020 – On 3 November 2020, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 17 billion to be executed during a 12-month period beginning 5 February 2020.Under the programme initiated 3 November 2020, Novo Nordisk will repurchase B shares for an amount up to DKK 2.7 billion in the period from 4 November 2020 to 1 February 2021.Since the announcement as of 23 November 2020, the following transactions have been made: Number of B sharesAverage purchase priceTransaction value, DKK Accumulated, last announcement1,495,000 644,067,193 23 November 2020120,000421.8150,616,939 24 November 2020120,000417.2950,075,364 25 November 2020120,000413.3249,598,976 26 November 2020120,000414.7049,763,473 27 November 2020120,000415.4149,849,433 Accumulated under the programme2,095,000 893,971,378 The details for each transaction made under the share repurchase programme are published on novonordisk.com.With the transactions stated above, Novo Nordisk owns a total of 35,618,659 B shares of DKK 0.20 as treasury shares, corresponding to 1.5% of the share capital. The total amount of A and B shares in the company is 2,350,000,000 including treasury shares.Novo Nordisk expects to repurchase B shares for an amount up to DKK 17 billion during a 12-month period beginning 5 February 2020. As of 27 November 2020, Novo Nordisk has since 5 February 2020 repurchased a total of 35,680,522 B shares at an average share price of DKK 424.81 per B share equal to a transaction value of DKK 15,157,400,848.Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 44,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.Further informationMedia:   Anne Margrethe Hauge+45 4442 3450amhg@novonordisk.com Ken Inchausti (US)+1 609 240 9429kiau@novonordisk.com     Investors:   Daniel Muusmann Bohsen+45 3075 2175dabo@novonordisk.com Valdemar Borum Svarrer+45 3079 0301jvls@novonordisk.com Ann Søndermølle Rendbæk+45 3075 2253arnd@novonordisk.com Mark Joseph Root+45 3079 4211mjhr@novonordisk.com Kristoffer Due Berg (US)+1 609 235 2989krdb@novonordisk.com Company announcement no. 73 / 2020Attachment * CA201130_Safe_Harbour